INTRODUCTION {#s1}
============

A series of Japanese cases characterized by dilated cardiomyopathy (DCM) and hyper-CKemia with no or minimal limb-girdle muscle symptoms and normal intelligence caused by a compound heterozygous mutation of 3 kb retrotransposal insertion and missense mutation in fukutin (*FKTN*) were first described by Murakami *et al*. \[[@OMV056C1]\]. Currently, it is designated 'cardiomyopathy dilated 1X (CMD1X: \#611615)' in the OMIM database. Only eight cases limited to the Japanese family have been reported so far. This is the first report describing a pregnancy case complicated with CMD1X.

CASE REPORT {#s2}
===========

A 25-year-old primiparous woman who had been diagnosed as CMD1X at the age of 19 was referred to our hospital at 6 weeks of gestation. Prior to the genetic diagnosis, she had manifested with exertional dyspnea and mild muscular weakness at neck and proximal extremities. DCM was confirmed in her echocardiogram showing systolic dysfunction with ventricular dilatation and left ventricular ejection fraction (EF) of 41%. Diffuse muscle atrophy and mild necrosis-regeneration process had found in biceps brachii muscle biopsy. Immunohistochemical analysis of biopsied muscle sample had shown a reduced α-dystroglycan staining and a normal pattern of the distribution and expression of β-dystroglycan. As previously reported \[[@OMV056C2]\], the analysis of her genomic DNA using the polymerase chain reaction technique had revealed a compound heterozygous mutation of 3 kb retrotransposal insertion. In addition, a direct sequencing of all the exons and adjacent introns of *FKTN* had shown a missense mutation (c.302G\>T, p.Cys101Phe).

In the first trimester of her pregnancy, echocardiography demonstrated diffused left ventricular hypokinesis accompanied with left ventricular dilatation. EF was 47% and left ventricular diastolic dimension (LVDd) was 53 mm. Her clinical findings at 10 weeks of gestation are demonstrated in Table [1](#OMV056TB1){ref-type="table"}. The limitation level of her physical activity was class II in New York Heart Association (NYHA) functional classification. Mild muscular weakness at neck, rhomboids and gluteus medius along with bilateral calf hypertrophy was demonstrated in her neuromuscular evaluation and a waddling gait was observed. Her tendon reflexes in biceps, brachioradialis and triceps were suppressed. She and her husband opted to continue pregnancy after our counseling about the risk for maternal cardiac failure at term and postpartum and the possible adverse outcome in the fetus. Medication with β-blocker to prevent the progression of DCM was continued during pregnancy. From 28 weeks of gestation, she was hospitalized for a concern of increase in the cardiac load in the third trimester and received intensive evaluation for her cardiac function. From 30 weeks of gestation, cardiothoracic ratio on chest X-ray and LVDd on echocardiogram increased progressively together with gradual elevation of peripheral concentration of brain natriuretic peptide (BNP; Fig. [1](#OMV056F1){ref-type="fig"}). Although subjective symptom related to cardiac failure was not obvious at bed rest, allowing pregnancy to continue until term could cause irreversible deterioration of cardiac function. Therefore, she underwent an elective cesarean section at 35 weeks of gestation and gave birth to a healthy male baby (birth weight: 2306 g, Apgar score 8 point at 5 min). Table 1:Clinical findings at 10 weeks of gestationClinical laboratory dateEchocardiographyWBC5.4 × 10^3^/μlTP6.1 g/dlIVS/PWth6/5 mmHb12.3 g/dlAlb3.7 g/dlLVDd/Ds51/42 mmPlt20.5 × 10^4^/μlLDH302 U/lEF47%T-Bil1.1 mg/dlAoD25 mmPT-INR0.93Glu71 mg/dlLAD36 mmAPTT26.9 sBUN5.1 mg/dlAsynergyPosterior wallFbg304 mg/dlCre0.26 mg/dlNa140 mEq/lK4.1 mEq/lCK1873 U/lCK-MB52 U/lBNP45.3 pg/ml Figure 1:Transition of cardiac function and BNP before 35 weeks.

A transient elevation of peripheral BNP was found at postoperative day (POD) 7 and was normalized at POD 14 (Fig. [2](#OMV056F2){ref-type="fig"}). In two weeks after delivery, the parameters of cardiac function on echocardiogram and the level of daily activity both recovered to the conditions comparable to those before pregnancy. At postpartum, she realized worsening of muscular weakness and had some difficulty in climbing stairs and holding her baby. She was discharged with her baby at POD 17. Figure 2:Transition of BNP, CK and CK-MB after operation.

DISCUSSION {#s3}
==========

Genetic diseases associated with *FKTN* gene defect include Fukuyama congenital muscular dystrophy, Walker-Warburg syndrome, limb-girdle muscular dystrophy type 2M (LGMD2M) and CMD1X. A gene product of *FKTN* participates in glycosylation of α-dystroglycan, which controls the linkage between extracellular and intracellular proteins \[[@OMV056C3]\]. Defect of the *FKTN* gene could lead to muscular dystrophy, a developmental disturbance of central nervous system and eye anomalies \[[@OMV056C4]\]. Murakami *et al*. \[[@OMV056C1]\] first identified a compound heterozygous *FKTN* mutation, showing DCM with no or minimal LGMD symptom and normal intelligence. This genetic disease was currently categorized as CMD1X. Similar to Fukuyama congenital muscular dystrophy, muscle biopsy of patients with CMD1X indicated altered glycosylation of α-dystroglycan, although minimal dystrophy was histologically detected in skeletal muscle. A molecular mechanism for cardiomyopathy-dominant disease phenotype with mildest skeletal muscular dystrophy in CMD1X is not clarified.

Clinical cases of CMD1X have been limited to eight Japanese so far. To our knowledge, there is no preceding report on pregnancy of a patient with CMD1X. Pregnancy has a negative impact on the cardiac function in the women with DCM \[[@OMV056C5]\]. A previous prospective study found that adverse maternal cardiac event occurred in 39% of pregnancies complicated with DCM \[[@OMV056C6]\]. In addition, the incidence of the cardiac event was significantly higher if any of three risk factors, moderate or severe LV dysfunction (EF \<45%), NYHA functional class III or IV and/or a previous cardiac event was present. In this context, the present case was at moderate risk, showing borderline values of EF, 41% prior to pregnancy and 48% in the first trimester. Generally, it is known that the increase in intravascular volume and cardiac output in the third trimester elevates the risk for adverse cardiac event in pregnant women with DCM \[[@OMV056C5]\]. In the present case, the pregnancy period can be extended until 35 weeks without irreversible exacerbation of cardiac failure at postpartum, although the progress of cardiac dysfunction was manifested from 30 weeks. Regarding the prenatal management conducted in this case, the medication with β-blocker and the prophylactic hospitalization for bed rest might contribute to preservation of cardiac function, leading to the extension of pregnancy without severe adverse cardiac event.

She recognized the worsening of muscular weakness at postpartum. According to a previous study on pregnancy outcome in women with hereditary neuromuscular disorders, persistent worsening of muscular symptoms was experienced in 54% of LGMD pregnancies, whereas walking ability was maintained in nearly all women who had been ambulant before pregnancy \[[@OMV056C7]\]. Therefore, the progression of muscular dystrophy during pregnancy is possible in the present case. However, the influence of disuse syndrome should be considered, since long-term bed rest might have additional negative impact on the disease-specific muscular dysfunction.
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